False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Blood. 2018 Jun 7;131(23):2596-2598. doi: 10.1182/blood-2017-12-822940. Epub 2018 Apr 18.

Theodore W Laetsch^{1

2}, Shannon L Maude^{3

4}, Michael C Milone^{5

6}, Kara L Davis⁷, Joerg Krueger⁸, Ana Maria Cardenas^{6

9}, Lamis K Eldjerou¹⁰, Christopher H Keir¹⁰, Patricia A Wood¹⁰, Stephan A Grupp^{3

4}

¹ Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, TX.
² Pauline Allen Gill Center for Cancer and Blood Disorders, Children's Health, Dallas, TX.
³ Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
⁴ Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, PA.
⁵ Center for Cellular Immunotherapies.
⁶ Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
⁷ Department of Pediatrics, Stanford University School of Medicine, Stanford, CA.
⁸ Division of Haematology/Oncology/BMT, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
⁹ Infectious Disease Diagnostics Laboratory, Children's Hospital of Philadelphia, Philadelphia, PA; and.
¹⁰ Novartis Pharmaceuticals Corporation, East Hanover, NJ.

No abstract available

Publication types